The rationale for using FDG avidity as a possible prognostic marker derives from prior studies demonstrating FDG avidity correlates with known histopathological and immunohistochemical markers of aggressive breast cancer biology, including ER/PR/HER2 status, histologic subtype, and tumor grade 20–23. The gene discussed is ESR1; the disease is breast carcinoma.